Taken together, the main findings of this study uncover an effective and potential T2D therapeutic by oral delivery of D‐mannose, which rescued both hepatic steatosis and diabetic bone loss through suppressing macrophage release of EVs based on metabolic control of CD36 expression (Figure 8). This evidence concerns the gene CD36 and type 2 diabetes mellitus.